NCT07214870View on ClinicalTrials.gov

A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

May 14, 2027

Study Completion Date

May 14, 2027

Conditions
Fatty Liver Disease
Interventions
DRUG

NNC4005-001

NNC4005-0001 will be given as a single ascending dose via subcutaneous route

DRUG

Placebo

Placebo matched to NNC4005-0001 will be given via subcutaneous route

Trial Locations (1)

H3P 3P1

Altasciences, Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY